Differential Diagnosis for Facial Pain: Trigeminal Neuralgia, Cluster Headache, Acute Sinusitis, Bell’s Palsy, and Temporal Arteritis

Facial pain can be caused by a variety of conditions, and it is important to differentiate between them in order to provide appropriate treatment. Here are five possible diagnoses for facial pain:

1. Trigeminal Neuralgia: This condition causes sudden, sharp shooting pain in the distribution of one or more branches of the trigeminal nerve. The pain is often triggered by light touch, eating, talking, or exposure to the cold.

2. Cluster Headache: Recurrent attacks of severe pain around the eye or temporal region, which tend to occur at the same time each day, eg on waking.

3. Acute Sinusitis: This condition presents with nasal blockage or discharge, facial pain or pressure, and sometimes a reduction or loss of smell.

4. Bell’s Palsy: This condition typically presents with facial weakness, pain behind the ear, earache, aural fullness, or facial palsy.

5. Temporal Arteritis: This condition presents with a localised, unilateral headache around the temporal region, tenderness over the area with redness and pulsation.

It is important to consider all of these diagnoses when evaluating a patient with facial pain, and to provide appropriate management based on the specific condition.

Palliative care prescribing for pain is guided by NICE and SIGN guidelines. NICE recommends starting treatment with regular oral modified-release or immediate-release morphine, with immediate-release morphine for breakthrough pain. Laxatives should be prescribed for all patients initiating strong opioids, and antiemetics should be offered if nausea persists. Drowsiness is usually transient, but if it persists, the dose should be adjusted. SIGN advises that the breakthrough dose of morphine is one-sixth the daily dose, and all patients receiving opioids should be prescribed a laxative. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred to morphine in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and all patients should be considered for referral to a clinical oncologist for further treatment. When increasing the dose of opioids, the next dose should be increased by 30-50%. Conversion factors between opioids are also provided. Opioid side-effects are usually transient, such as nausea and drowsiness, but constipation can persist. In addition to strong opioids, bisphosphonates, and radiotherapy, denosumab may be used to treat metastatic bone pain.

Overall, the guidelines recommend starting with regular oral morphine and adjusting the dose as needed. Laxatives should be prescribed to prevent constipation, and antiemetics may be needed for nausea. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and referral to a clinical oncologist should be considered. Conversion factors between opioids are provided, and the next dose should be increased by 30-50% when adjusting the dose. Opioid side-effects are usually transient, but constipation can persist. Denosumab may also be used to treat metastatic bone pain.

Loratadine and cetirizine are antihistamines that are not likely to cause sedation, unlike chlorpheniramine which is known to be more sedating.

While loratadine may still cause sedation, it is less likely to do so compared to other antihistamines such as chlorphenamine and promethazine. Buclizine, on the other hand, is primarily used as an anti-emetic for migraines but also has antihistamine properties. Mirtazapine, although it has antihistamine properties, is mainly used as an antidepressant and appetite stimulant.

Antihistamines for Allergic Rhinitis and Urticaria

Antihistamines, specifically H1 inhibitors, are effective in treating allergic rhinitis and urticaria. Sedating antihistamines such as chlorpheniramine have antimuscarinic properties that can cause side effects like urinary retention and dry mouth. On the other hand, non-sedating antihistamines like loratidine and cetirizine are less likely to cause drowsiness. However, there is some evidence that cetirizine may still cause more drowsiness compared to other non-sedating antihistamines. Overall, antihistamines are a valuable treatment option for those suffering from allergic rhinitis and urticaria.

Breast Masses: Differential Diagnosis and Clinical Features

Breast masses are a common concern for women, and it is important to differentiate between benign and malignant causes. Here, we discuss the clinical features and differential diagnosis of various breast masses.

Diffuse cystic mastopathy is a benign condition that affects a significant proportion of women. It is characterized by the formation of cysts in the breast lobules due to hormonal changes in the menstrual cycle. The lumps are smooth, mobile, and tend to peak in size before each period. Diagnosis is primarily based on clinical examination, but a biopsy may be needed to confirm the diagnosis.

Fat necrosis is another benign condition that can occur due to direct trauma or surgery. It is characterized by the formation of firm, round, and painless masses in the breast. The skin around the lump may be red or bruised, and a biopsy may be needed to differentiate it from breast cancer.

Breast abscesses are characterized by local inflammation, pain, and fever. They may be associated with previous breast infections and may require drainage. However, there is no evidence of an infectious process in this patient.

Breast cancer is a concern in any patient with a breast mass, but early breast cancer is often asymptomatic. Physical findings that may indicate the possible presence of breast cancer include changes in breast size or shape, skin dimpling or changes, nipple abnormalities, and axillary lumps. However, none of these symptoms are present in this patient.

Fibroadenoma is the most common cause of breast mass in women under 35 years of age. It is characterized by a singular, firm, rubbery, smooth, and mobile mass. However, this patient reports multiple lumps, making a diagnosis of fibroadenoma less likely.

In conclusion, the cyclic nature of this patient’s breast masses makes diffuse cystic mastopathy the most likely diagnosis. However, a biopsy may be needed to confirm the diagnosis and rule out other causes.

Contraception is still necessary after menopause. Women who are over 50 years old should use contraception for at least 12 months after their last period, while those under 50 years old should use it for at least 24 months after their last period.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

A thickened brown velvety patch of skin, often accompanied by skin tags, is a common sign of Acanthosis nigricans (AN). This condition is typically found in the axilla, groin, and back of the neck. However, AN is not a standalone condition, but rather a cutaneous sign of underlying disease. The most common type of AN is associated with obesity and insulin resistance. Other underlying conditions linked to AN include Cushing’s syndrome, polycystic ovary syndrome, and certain medications such as nicotinic acid, insulin, and systemic corticosteroids. In rare cases, AN may indicate an underlying malignancy, particularly stomach cancer. Therefore, it is crucial to consider this possibility when making a diagnosis.

Acanthosis nigricans is a condition characterized by the presence of symmetrical, brown, velvety plaques on the neck, axilla, and groin. This condition can be caused by various factors such as type 2 diabetes mellitus, gastrointestinal cancer, obesity, polycystic ovarian syndrome, acromegaly, Cushing’s disease, hypothyroidism, familial factors, Prader-Willi syndrome, and certain drugs like the combined oral contraceptive pill and nicotinic acid. The pathophysiology of acanthosis nigricans involves insulin resistance, which leads to hyperinsulinemia. This, in turn, stimulates the proliferation of keratinocytes and dermal fibroblasts through interaction with insulin-like growth factor receptor-1 (IGFR1).

Orbital Cellulitis in Penicillin-Allergic Patients

When treating orbital cellulitis in a patient with a penicillin allergy, it is important to choose the right antibiotics. Cefuroxime IV alone is not enough and should be combined with metronidazole. Co-amoxiclav IV is not appropriate for penicillin-allergic patients. Tazocin® IV should also be avoided. The best option is a combination of clindamycin and ciprofloxacin IV. It is important to note that drainage of the orbit is not necessary unless there are signs of an abscess. By choosing the right treatment, we can effectively manage orbital cellulitis in penicillin-allergic patients.

In cases where there is a need for urgent psychiatric assessment, GPs may utilize Section 4 of the Mental Health Act. This can be done with the assistance of an AMHP or NR, and allows for the emergency transfer of the patient. Unlike Section 2, which requires the agreement of two psychiatrists, Section 4 is used when there is a risk of unacceptable delay in the patient’s care. It provides a 72-hour window for assessment, after which it is typically converted to a Section 2. Additionally, the police have the authority under Section 135 and 136 to take a patient to a safe location for psychiatric evaluation.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

Treatment Options for Kawasaki Disease: Understanding the Use of Aspirin

Kawasaki disease is a condition that affects children and causes inflammation in the blood vessels throughout the body. When diagnosed, treatment typically involves intravenous immunoglobulin and aspirin. In this article, we will discuss the use of aspirin in the treatment of Kawasaki disease and why it is important.

Oral aspirin is given to patients with Kawasaki disease due to its anti-inflammatory and antiplatelet properties. It helps to reduce the chances of blood clots if there are developing problems in the heart, such as coronary artery aneurysms that can occur in Kawasaki disease. The dosage of aspirin is usually higher (30 mg/kg per day) for up to two weeks and then continued at lower doses (3-5 mg/kg per day) until a review of echocardiogram, which is usually 6-8 weeks after the onset of illness.

If the review echocardiogram at 6-8 weeks shows no evidence of any coronary artery aneurysms, then aspirin is usually stopped. However, until that time, patients with Kawasaki disease will continue to take oral aspirin daily.

It is important to note that other non-steroidal anti-inflammatory medications such as ibuprofen should be avoided while taking aspirin. Additionally, oral steroids are a second-line treatment that are considered when there is failure to respond to initial intravenous immunoglobulin therapy.

In conclusion, aspirin is an important part of the treatment for Kawasaki disease due to its anti-inflammatory and antiplatelet properties. Patients with Kawasaki disease will continue to take oral aspirin daily until a review echocardiogram shows no evidence of any coronary artery aneurysms. It is important to follow the treatment plan prescribed by a specialist to ensure the best possible outcome for the patient.

Based on the electrocardiogram (ECG) findings, the most likely diagnosis for this patient is an inferior myocardial infarction (MI), which occurs in the territory of the right coronary artery. This is indicated by ST-segment elevations in leads I, II, and aVF. Other ECG changes, such as complete heart block and bradycardia, may also be present due to the arterial supply the RCA gives to the atrioventricular and sinoatrial nodes. It is important to note that a new left bundle branch block (LBBB) may suggest acute coronary syndrome.

Acute pericarditis is unlikely as it presents with sharp retrosternal chest pain and a pericardial friction rub on auscultation, with different ECG findings such as widespread concave ST-segment elevations and PR segment depression.

An anterolateral MI would show ST-segment elevations in the anterolateral leads, while a posterior MI would show ST-segment depressions in the anterior leads with tall R waves.

In a pulmonary embolism (PE), ECG changes may include a large S wave in lead I, a large Q wave in lead III, and an inverted T wave in lead III – S1Q3T3, but this is only seen in a minority of patients. Most patients with a PE would have a normal ECG or sinus tachycardia, with signs of right-heart strain sometimes present. The clinical presentation of a PE would also differ from that of an MI, with symptoms such as tachypnea, tachycardia, lung crackles, fever, pleuritic chest pain, dyspnea, and hemoptysis.